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A B S T R A C T
Multiple sclerosis (MS) is an inflammatory, demyelinating, neurodegenerative, immune-mediated disease pri-
marily diagnosed in early adulthood. Multiple sclerosis mostly impacts women of reproductive potential, with
pregnancy and birth outcomes being major concerns for many patients. While there is ample evidence that the
disease itself has no impact on pregnancy, many women living with MS still question their ability to have
children, and the impact of childbearing on their disease in the short and long term. Such questions emphasize
the importance of proper guidance from healthcare professionals, particularly neurologists. Management con-
siderations are also complicated by the growing list of available treatment options. This review will summarize
current evidence and expert opinion around the management of female MS patients of reproductive potential,
from family planning to the postpartum period. Current guidelines on the use of disease-modifying therapies
throughout pregnancy will be discussed, as well as other general medical recommendations, to minimize MS
disease activity in the peripartum period.
1. Introduction
Multiple sclerosis (MS) is the most common chronic neurological
immune-mediated disorder of young adults, and is more commonly
seen in women (Hauser and Oksenberg, 2006). The prevalence of MS
has been increasing over the past few decades and is now approxi-
mately three times more common in women than in men (Harbo et al.,
2013; Koch-Henriksen et al., 2018). Owing to both the increasing in-
cidence of MS in women, as well as an increasing number of available
therapies, MS is becoming a substantial and growing clinical burden for
women of reproductive potential (Altintas et al., 2015; MS International
Federation, 2013; Nguyen et al., 2019).
Adequate guidance for female MS patients who plan to conceive
remains an unmet medical need (Borisow et al., 2014). Obstetricians
often lack experience in MS, and neurologists frequently have limited
knowledge about the obstetric and pregnancy implications of MS
(Borisow et al., 2014; Coyle et al., 2004). Moreover, the increasing
number of distinct disease-modifying therapies (DMTs), and potential
side effects, complicate the management of women with MS con-
sidering pregnancy. They need a treatment plan which minimizes the
likelihood of relapses, while balancing risk to the fetus and mother
(Vukusic and Marignier, 2015).
There are a lack of robust clinical studies and evidence-based
guidelines on clinical decision-making and therapeutic choices during
pregnancy (Wundes et al., 2014). Furthermore, there are uncertainties
pertaining to appropriate management strategies in female MS patients
throughout the stages of pre-conception, pregnancy, and the post-
partum period. This overview of current knowledge and clinical prac-
tice, by specialist neurologists experienced in the treatment of women
with MS, provides guidance on the management and care of female MS
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Table 1
Patient concerns and advice before, during, and after pregnancy.
Concern Guidance
Pre-pregnancy
Fertility and fetal development In general, there is no evidence of an association between maternal MS and adverse effects on fetal development. The
effect of MS on fertility is uncertain; blood hormone abnormalities have been observed in female patients with MS which
may affect fertility, but this still requires substantiation (Hellwig and Correale, 2013; Lombardi et al., 2011; Roux et al.,
2015; Yalcin et al., 2017)
Assisted reproductive technology/in vitro
fertilization
Use of gonadotropin-releasing hormone agonists and antagonists, if pregnancy does not occur, may be associated with
temporary increased risk of relapses (Hellwig, 2014)
Contraceptive use No evidence for negative impact on MS disease course. LARC methods may be particularly effective, as they do not require
proactive user compliance (Houtchens et al., 2017)
Sexual dysfunction Observed in up to 63% of women; may require specific counseling and treatments (Kim et al., 2018; Lew-Starowicz and
Gianotten, 2015)
Genetic risk MS is not considered to be inherited, but risk of developing MS is modestly increased when a parent has MS (Coyle, 2016)
DMT use and washout Therapy dependent; no washout is reasonable for glatiramer acetate (GA), interferon beta (IFNβ), dimethyl fumarate
(DMF), or natalizumab (Coyle, 2016)
Lifestyle Women should be counseled to take prenatal vitamins, avoid alcohol and smoking, and maintain a healthy diet
(Coyle, 2016)
During pregnancy
Impact of pregnancy on MS prognosis Pregnancy is associated with a marked decrease in disease activity during the third trimester, followed by an increase in
the postpartum period. No long-term negative impact on relapsing MS (Confavreux et al., 1998; Coyle, 2016)
Impact of MS on pregnancy outcome No increase in ectopic pregnancies, birth defects, miscarriage, or stillbirths (Hellwig, 2014; Oreja-Guevara et al., 2014)
Treatment with DMTs during pregnancy Typically, DMTs are not used during pregnancy. Symptomatic treatment should be for short periods when appropriate and
necessary. Glucocorticoids can be used for relapses at any time during pregnancy. Magnetic resonance imaging (MRI) may
be carried out if there is good reason. Use of contrast should be avoided (unless absolutely necessary) (Airas and Kaaja,
2012; Alroughani et al., 2016)
At delivery and postpartum
Delivery and anesthesia Use of anesthesia should be based solely on experienced obstetric clinical decision-making (Lu et al., 2013a; Pasto et al.,
2012)
Breastfeeding Data on DMT transfer to breast milk and negative effects in newborns are lacking. Since patients with more active disease
would benefit from early DMT resumption after delivery, the potential risk of DMT exposure to the infant during
breastfeeding should be considered (Almas et al., 2016)
Disease activity The first 3 months postpartum are a high-risk period for increased clinical and MRI disease activity, after which time
activity reverts to the pre-pregnancy level (Alroughani et al., 2018; Confavreux et al., 1998)
Use of DMTs DMTs can usually be reinstated soon after delivery (Coyle, 2016)
Economic/social impact Pregnancy does not produce disability; choosing to have a child should not be directed by a diagnosis of MS (Coyle, 2016)
Child development Maternal MS is not thought to have a negative impact on the mental health status of the child (Andersen et al., 2018)
DMT, disease-modifying therapy; LARC, long-acting reversible contraceptive; MRI, magnetic resonance imaging; MS, multiple sclerosis.
P.K. Coyle, et al. Multiple Sclerosis and Related Disorders 32 (2019) 54–63
55
Downloaded for Anonymous User (n/a) at BS - University of Copenhagen from ClinicalKey.com by Elsevier on May 29, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
patients from family planning through to the postpartum period.
2. Patients not planning on pregnancy
For female patients who are not actively planning a pregnancy,
healthcare professionals (HCPs) should provide helpful information
about available contraception. There are existing guidelines, such as
those provided by the American College of Obstetricians and
Gynecologists (ACOG) (The American College of Obstetricians and
Gynecologists, 2015), the US Center for Disease Control and Prevention
(CDC) (Centers for Disease Control and Prevention, 2018), the Faculty
of Sexual and Reproductive Health (FSRH) (Faculty of Sexual and
Reproductive Health, 2016), and the World Health Organization
(WHO) (World Health Organization, 2015), on contraceptive use in
women of reproductive potential. These include information on specific
contraceptives, as well as family planning. However, there is a clear
need for additional guidance for use of contraceptives in women with
specific neurologic conditions. The US Medical Eligibility Criteria for
Contraceptive Use (US MEC), the FSRH UK MEC, and the WHO MEC
provide evidence-based guidance on contraceptive use in the general
population (Curtis et al., 2016; Faculty of Sexual and Reproductive
Health, 2016; World Health Organization, 2015). More recently, the US
MEC has been updated to include similar recommendations for patients
with MS (Curtis et al., 2016). The MS Trust, an online resource in the
UK, also provides guidance for the use of hormonal contraceptives
based on potential interactions with DMTs (https://www.mstrust.org.
uk/a-z/contraception). Since female patients with MS first discuss their
family planning with their neurologist, the ability of the neurologist to
provide accurate information about contraceptive options is important
(Bove et al., 2014; Siroos and Harirchian, 2014).
Guidelines provided by the WHO and ACOG indicate that all pa-
tients, depending on their medical eligibility, should have access to all
contraceptive methods, including long-acting reversible contraceptive
(LARC) methods (intrauterine devices, implantable rods), tubal ster-
ilization, hormonal contraceptives, and barrier methods (The American
College of Obstetricians and Gynecologists, 2015; World Health
Organization, 2015). Most contraceptive methods appear effective and
safe for women with MS. LARC methods may be particularly appro-
priate in female patients because, once positioned, they do not require
proactive user compliance (Houtchens et al., 2017; The American
College of Obstetricians and Gynecologists, 2015). According to the
WHO, UK MEC and US MEC, progestin-only and combined hormonal
contraceptives are not recommended for patients with prolonged im-
mobility, because of increased risk of venous thromboembolism and
concerns about decreased bone mineral density (Curtis et al., 2016;
Faculty of Sexual and Reproductive Health, 2016; Houtchens et al.,
2017; World Health Organization, 2015).
Primary care providers and obstetricians/gynecologists (OB/GYNs)
may benefit from additional up-to-date education about the use of
contraceptives in women living with MS. In general, there is no inter-
action between DMTs and oral contraceptives. Formal drug–drug in-
teraction (DDI) studies are limited; however, DDI studies have been
carried out to assess the efficacy of oral contraceptives with concurrent
delayed-release dimethyl fumarate (DMF) and fingolimod therapy
(David et al., 2012; Zhu et al., 2017). In these studies, there were no
reciprocal pharmacokinetic effects between DMF or fingolimod and oral
contraceptives. Teriflunomide has also not shown any clinically re-
levant effect on the pharmacokinetics of oral contraceptives
(Genzyme Corp., 2016). While increases in mean ethinylestradiol and
levonorgestrel levels have been observed following repeat doses of
teriflunomide, this interaction has not been shown to impact contra-
ceptive efficacy (Genzyme Corp., 2016; Miller, 2015).
3. Family planning
HCPs advising female MS patients considering pregnancy must
address several factors, including fertility, treatment choice, delivery,
and the potential effects of pregnancy on MS disease activity and course
(Table 1). Living with MS can have a significant impact on family
planning decisions; in surveys of patients with MS, up to 77% have
reported that their intended number of pregnancies changed as a result
of their diagnosis (Carvalho et al., 2014). MS symptoms that may in-
terfere with parenting, and fear of disability worsening, are the most
common reasons contributing to these pregnancy-related decisions.
Lack of education, specifically with regard to treatment possibilities
during pregnancy, is a significant concern among both men and women
with MS. In a recent Danish survey of 590 patients with MS, 47% of
patients felt inadequately informed about DMT use during pregnancy
(Rasmussen et al., 2018). More ‘holistic’ concerns of women living with
MS, including the well-being of the child, ability to cope with par-
enting, societal attitudes, and genetic counseling (Prunty et al., 2008;
Skinner et al., 2015), also contribute, although these are beyond the
scope of this paper.
3.1. Fertility
Blood hormone abnormalities have been observed in female pa-
tients with MS which may affect fertility, but this still requires sub-
stantiation (Hellwig and Correale, 2013; Lombardi et al., 2011; Roux
et al., 2015). Women with MS also tend to have fewer pregnancies and
childbirths before they first experience clinical symptoms; however, it is
not known if this lower number of pregnancies is a direct result of
having MS (Magyari et al., 2013). Sexual dysfunction is also common
among patients with MS. In a recent meta-analysis of 14,538 patients
living with all types of MS, 63% of women and 61% of men reported
challenges with sexual dysfunction (Kim et al., 2018). Despite its pre-
valence, pharmacologic treatment and advice for managing sexual
dysfunction in patients with MS is lacking (Lew-Starowicz and
Gianotten, 2015).
The prevalence of impaired fecundity ranges from 10 to 15% per-
cent in the US general population (in women between the ages of
15–44) to over 30% in the European general population (in women
between the ages of 35–44) (Chandra et al., 2013; ESHRE Capri
Workshop Group, 2010). In comparison, approximately 10% of women
living with MS have difficulty becoming or staying pregnant
(Coyle, 2016). Assisted reproductive technology (ART) can be used,
which includes in vitro fertilization and fertility treatments in which
eggs and embryos are handled, with success rates as high as 31% in the
US and 22% in the European general population (Calhaz-Jorge et al.,
2017; Centers for Disease Control and Prevention, 2018). In a recent
study from the New England Pregnancy Prospective Cohort Study
(PREG-MS), 14% of patients successfully conceived through the use of
fertility treatments (Manieri et al., 2018). While there are a limited
number of studies on the effect of ART in female MS patients, there is an
association with increased relapse risk, particularly in the first 3 months
after unsuccessful cycles (Rankin et al., 2018). This has also been ob-
served when gonadotropin-releasing hormone (GnRH) agonists are
used; in a French, retrospective study of 32 patients with MS, significant
increases in relapse rates three months after IVF treatment were ob-
served in patients receiving GnRH agonists (Hellwig, 2014; Michel
et al., 2012). Similar risks have not been observed after use of GnRH
antagonists (Coyle, 2016; Michel et al., 2012). Recent reports suggest
that continued DMT use may prevent this relapse risk and have ques-
tioned whether both agonists and antagonists carry a risk
(Brzosko et al., 2018). Ultimately, a loss of pregnancy may be more of a
trigger for MS activity than the type of ART used, but further research is
needed (Kaplan et al., 2018). Low Vitamin D levels are also commonly
reported in patients with MS and can impact fertility, and while not a
clinical requirement, Vitamin D level assessment prior to and during
pregnancy may be beneficial (Duan et al., 2014).
P.K. Coyle, et al. Multiple Sclerosis and Related Disorders 32 (2019) 54–63
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3.2. Pre-conception
Discussions on the risks and benefits of DMTs should occur as early
as possible with a patient and before any planned pregnancy
(Vukusic and Marignier, 2015). The US Food and Drug Administration's
decision to update labelling by referencing the Pregnancy Lactation and
Labelling Rule will help US HCPs evaluate benefit/risk (Office of the
Federal Register (US), 2014). DMTs are generally not recommended for
use during pregnancy unless the benefits outweigh the risks to the fetus,
and recommended washout periods for some DMTs should be con-
sidered prior to conception (Houtchens et al., 2017). Since pharma-
cotherapy should be limited during pregnancy, adequate control of MS
symptoms should be considered prior to conception (Coyle, 2016).
There are many considerations involved with family planning, in
both patients with MS and the general population, such as female age,
fertility status, and duration of non-conception (Cuello et al., 2017). In
general, the probability of conceiving decreases with age, particularly
in women over 33 years old (Wesselink et al., 2017). In patients with
MS, disease activity should be stable in patients for 1 year prior to
conception to diminish the risk of postpartum relapses (Wesselink et al.,
2017). Early initiation of DMTs following an MS diagnosis, and sub-
sequent DMT adherence, is a critical component of MS management, as
higher relapse rates pre-pregnancy are associated with higher relapse
rates in the postpartum period (Alroughani et al., 2018). Consequently,
prolonged washouts prior to conception should be avoided to minimize
time off therapy (Coyle, 2016). A potential (albeit unproven) alter-
native for women with a high risk of relapse is the use of monthly
pulsed corticosteroids, which may be used until pregnancy is achieved
(Bove et al., 2014).
DMT washout periods should be as short as possible (Table 2)
(Coyle, 2016). Given the teratogenic effects observed with fingolimod
(Novartis Pharmaceuticals Corp., 2018) and teriflunomide
(Genzyme Corp., 2016) in animal studies, use of these therapies should
be terminated prior to conception, and washout periods should be
considered. DMTs with a short half-life, such as DMF which has a
terminal half-life of 1 h (Biogen, 2017), do not require a washout;
however, washout periods should be considered for DMTs with longer
half-lives (e.g., teriflunomide and ocrelizumab). Teriflunomide-treated
patients should undergo an accelerated elimination procedure to ra-
pidly decrease plasma drug levels (Genzyme Corp., 2016). For natali-
zumab, a washout period is not specified, and its use during pregnancy
should be reserved for patients only with significant disease activity
following a benefit–risk evaluation (Montalban et al., 2018). While
reproductive toxicity (i.e., negative effects on embryofetal develop-
ment) and hematologic abnormalities in newborns have been observed
following natalizumab exposure, the rate of these adverse events is
comparable with the general population (Haghikia et al., 2014; Hellwig
et al., 2011). As a precaution, given the high frequency of hematolo-
gical abnormalities, natalizumab use during the third trimester should
only be considered as a last resort (Haghikia et al., 2014). Routine
screening for these abnormalities should be performed as long as na-
talizumab is being used during pregnancy. Extended interval dosing
every 6–8 weeks may also be performed to reduce exposure to natali-
zumab while preventing breakthrough disease activity (Bomprezzi and
Pawate, 2014). Alternatively, glatiramer acetate (GA) and interferon
beta (IFNβ) may be used in patients who wish to become pregnant, as
neither therapy has been associated with negative pregnancy effects in
humans (Coyle, 2016).
Patients receiving DMTs with non-continuous dosing regimens, such
as cladribine, should avoid pregnancy until the washout period fol-
lowing the last dose is complete. Women receiving cladribine should
use effective contraception during treatment and for at least 6 months
after the last dose. Patients should also consider both a hormonal and
barrier contraceptive method for at least 4 weeks after the last dose in
each treatment year (Merck Serono Europe Ltd., 2018).
In patients receiving alemtuzumab, low to undetectable
concentrations of the drug have been detected in serum 30 days fol-
lowing each treatment course (Genzyme Corp., 2017). Hypothyroidism,
which has been observed in patients on alemtuzumab, may result in an
increased risk of miscarriage or other fetal effects; thyroid function tests
are required prior to treatment initiation and every 3 months thereafter
(Genzyme Therapeutics, 2018). Neonatal Graves’ disease has also been
noted due to placental transfer of anti-thyroid antibodies
(Genzyme Corp., 2017). For these reasons, women on alemtuzumab
should avoid pregnancy during treatment and for at least 4 months after
the last infusion (Genzyme Corp., 2017). A six-month washout period is
recommended in patients receiving ocrelizumab in the US (12 months
in Europe) (Genentech Inc., 2018; Roche Registration GmbH, 2018). If
ocrelizumab use is continued during pregnancy, and due to the risk of
B-cell depletion, B-cell counts should be checked in newborns. Live or
live-attenuated vaccines should not be administered prior to confirming
recovery of B-cell counts in these infants (Genentech Inc., 2018). Ri-
tuximab, which is indicated for hematologic malignancies and rheu-
matoid arthritis, has been used off-label for MS treatment in some
countries (Chakravarty et al., 2011). As there have been reported in-
cidences of congenital malformations and neonatal infections asso-
ciated with its use, patients should avoid pregnancy for up to 12 months
after rituximab exposure (Salzer et al., 2016).
3.3. Genetic risk
The risk of passing MS to children is a significant concern among
women living with MS. In a large North American Research Committee
on MS (NARCOMS) registry study, 35% of patients with MS cited this
potential risk as the reason for why they chose not to have children
after an MS diagnosis (Alwan et al., 2013). While the risk of inheriting
MS from a parent with the disease is low (2–3%), there are genetic risk
factors, such as HLA-associated variants, that may be inherited and
increase the risk of developing MS (Coyle, 2016; Olsson et al., 2016; Xia
et al., 2016). Recent genome-wide association studies (GWAS) have also
demonstrated that families with multiple MS cases carry more MS-as-
sociated susceptibility variants than families with fewer affected re-
latives (Isobe et al., 2013). However, there are many additional factors
that play a role in MS pathogenesis, such as environmental factors,
incomplete penetrance, and epigenetic changes (Kucukali et al., 2015).
Despite this, regular pre-conception genetic testing for risk factors as-
sociated with MS is not currently available (Buraga and
Popovici, 2014).
4. Pregnancy
4.1. General medical management
While not a requirement, given the association between Vitamin D
deficiency and increased MS risk, women with MS should be advised to
take prenatal vitamins including Vitamin D and folic acid (Coyle, 2016;
Jalkanen et al., 2015). To ensure adequate supplementation, Vitamin D
levels should be monitored throughout pregnancy (Lerchbaum and
Rabe, 2014). As in the general population, patients should also avoid
alcohol and smoking, and ensure adequate sleep and a balanced diet
during pregnancy (Coyle, 2016). Since women with MS may be more
susceptible to urinary tract infections, special attention should be given
to the detection and treatment of such infections in pregnant women
with MS (Mahadeva et al., 2014).
While the amount of data available on DMT safety in patients who
become pregnant are increasing, those who have received DMTs at the
time of conception should still be encouraged to participate in a formal
pregnancy registry (Coyle, 2016). In newly diagnosed patients, preg-
nancy should be delayed until the disease is adequately controlled with
a DMT (1–2 years depending on disease activity) unless there is a
concern about rapidly declining fertility due to advanced age. HCPs
need to explain the pregnancy-related risks of DMTs within the context
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of the background rates of miscarriage and congenital abnormalities.
No DMT is considered entirely safe for use during pregnancy. However,
pregnant women who have been exposed to a variety of DMTs thus far
report obstetric and neonatal complications (e.g., malformations or
pregnancy complications) at rates similar to the general population
(Cree, 2013; Davenport et al., 2016; Dung and Panda, 2014; Fragoso
et al., 2010; Kieseier and Benamor, 2014; Salminen et al., 2010;
Vukusic et al., 2017). The decision to continue DMT use depends on
disease severity and the DMT in question (Table 3).
Data on pregnancy outcomes are starting to emerge for most DMTs.
However, only GA and the IFNβs (as a class) have more than a thousand
human exposures (Jesus-Ribeiro et al., 2017; Romero et al., 2015;
Sandberg-Wollheim et al., 2011). GA displays a favorable safety profile,
with congenital anomaly rates similar to those in the general population
in over 7000 exposures (Sandberg-Wollheim et al., 2018). There have
been over 2000 pregnancy exposures with IFNβ. In a study of 445
pregnant women with MS in the German Multiple Sclerosis and Preg-
nancy Registry, early exposure to IFNβ prevented significantly more
relapses compared to untreated patients and had no apparent effect on
pregnancy outcomes (Thiel et al., 2016). The long-term impact of na-
talizumab treatment on pregnancy outcomes is unclear. In an ob-
servational study of 376 MS or Crohn's disease patients in the Tysabri
Pregnancy Exposure Registry, there was no specific pattern of birth
defects that would suggest a drug association (Friend et al., 2016). In
patients receiving natalizumab, the combination of avoiding washout
prior to conception along with early resumption after delivery is most
effective for preventing maternal disease worsening (Portaccio et al.,
2018).
Overall, European Committee for Treatment and Research in
Multiple Sclerosis/European Academy of Neurology (ECTRIMS/EAN)
guidelines recommend IFNβ or GA use until the pregnancy is confirmed
(Montalban et al., 2018). Those with persistent high-disease activity
may also continue treatment with natalizumab, but only after a thor-
ough discussion of the potential implications with the patient. In very
active cases, alemtuzumab may continue to be used as long as con-
ception is avoided for at least 4 months after the last infusion
(Montalban et al., 2018). Pregnancy-related American Academy of
Neurology (AAN) practice guidelines are much less specific. Clinicians
are told to monitor reproductive plans, and counsel regarding re-
productive risks and use of birth control (Rae-Grant et al., 2018).
Relapse frequency typically decreases during pregnancy. In a recent,
retrospective, administrative claims US database study of 2867 women
with MS and live births, relapse rates decreased from approximately
1.7% in the 3 months before pregnancy to 1% in the first trimester
(Houtchens et al., 2018). Patients who continue to experience relapses
may benefit from corticosteroids. There are conflicting data suggesting
that corticosteroids may increase the risk of birth defects and mis-
carriage and so their use should be restricted to the treatment of acute
relapses that substantially impact daily life (Bjorn et al., 2015; Smets
et al., 2017). Different corticosteroids reach the fetus to different de-
grees. Approximately 100% of dexamethasone reaches the fetus, and
therefore should be avoided (Hellwig, 2014). Corticosteroids are safe
even during the first trimester and use does not increase risk for cleft lip
or palate (Skuladottir et al., 2014). Those with severe relapses
throughout pregnancy may benefit from methylprednisolone or pre-
dnisolone; these are metabolized and inactivated in the placenta
(Brookings and Lee, 2009). While data are limited, plasma exchange
may also be safe in women who experience severe relapses (Correia
et al., 2018; Cox et al., 2017). Overall, general pharmacotherapy for MS
symptoms during pregnancy (e.g., corticosteroids, analgesics, spasticity
treatment options, and antidepressants) should be evaluated carefully
and used at the minimum effective dose, for as short a time as possible.
4.2. Impact on MS disease activity and course
Pregnancy in MS does not appear to increase the risk of exacerba-
tions; in fact, a reduction in disease activity appears coincident with
increasing concentrations of gestation-related steroid hormones, among
other factors (Sicotte et al., 2002), which are most evident during the
final trimester (Coyle, 2016). In addition, studies have shown that
disability worsening is more rapid in nulliparous women compared to
multiparous women with MS (Teter et al., 2014). Previous choice of
DMT, however, can have an adverse impact; rebound disease activity
has been observed in patients after treatment discontinuation with
fingolimod or natalizumab (Clerico et al., 2017; Meinl et al., 2018).
The impact of pregnancy on relapse rates was first reported in the
seminal Pregnancy in Multiple Sclerosis study, a multi-center, pro-
spective, observational study examining the impact of pregnancy and
the postpartum state on MS disease activity in untreated patients
(Confavreux et al., 1998). Of the 254 pregnancies in this study, relapse
rates during the third trimester were reduced by 70% compared to the
year before pregnancy. Similar results have been observed in more
recent studies. In a retrospective, administrative claims database study,
which followed 2158 women living with MS and a live birth, adjusted
relapse rates per month were significantly lower during pregnancy
compared to the pre-pregnancy period; however, monthly adjusted
relapse rates increased from 0.99% in the third trimester of pregnancy
to 2.56% in the 6-week puerperium period (Houtchens et al., 2018).
Relapses before and during pregnancy are associated with an in-
creased risk of postpartum relapse (Hughes et al., 2014; Jesus-Ribeiro
et al., 2017). The potential influence of DMT treatment on postpartum
relapse rate was assessed in a prospective study of MS patients in the
Italian Pregnancy dataset; in this study, early introduction or resump-
tion of DMTs within the first 3 months post-birth was associated with a
reduced, albeit marginal, risk of postpartum relapses (Portaccio et al.,
2014). In an MSBase study of 893 pregnancies in women with MS, DMT
use in the 2 years prior to conception was protective against postpartum
relapses after delivery (Hughes et al., 2014).
The association between relapses and postpartum disease activity
prompts the need for standardized treatment guidelines (Jesus-
Ribeiro et al., 2017). International or country-specific guidance, such as
ECTRIMS/EAN (Montalban et al., 2018), AAN (Rae-Grant et al., 2018),
Table 3
Disease-modifying therapy recommendations in patients with mild/moderate and high disease activity.
Mild/moderate disease activity (≤1 relapses in prior year) High disease activity (≥2 relapses in prior year)
Treatment-naïve Delay pregnancy until 1 year of stability is achieved Delay pregnancy until disease is adequately controlled (1–2 years)
(Hughes et al., 2014)
On-treatment Discontinue treatment prior to pregnancy (with the exception of GA 20 and
40mg/mL and IFNβ, DMF, and natalizumab, which can be continued if
necessary)(Biogen, 2017, 2018a,b,c; Montalban et al., 2018)
Treatment with natalizumab during pregnancy, or alemtuzumab or cladribine
prior to pregnancy may be considered after discussion of the potential
implications. Conception should be delayed 6 (US) to 12 (EU) months after the
last dose of ocrelizumab (Genentech Inc., 2018; Montalban et al., 2018; Roche
Registration GmbH, 2018)
DMF, dimethyl fumarate; EU, European Union; GA, glatiramer acetate; IFNβ, interferon beta; US, United States.
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and the UK National Institute for Health and Care Excellence (NICE)
guidelines, emphasize the need for discussion of how pregnancy might
reduce relapse rates, with the possibility of a transient increase after
delivery (National Institute for Health and Care Excellence, 2014).
Treatment plans should balance the risk posed by the DMT to the fetus
and/or mother with regard to teratogenicity, fetotoxicity, and the po-
tential of further disease progression (Vukusic and Marignier, 2015).
4.3. Peripartum care guidelines
MS confers no increased risk for miscarriage or congenital mal-
formation. The course of a typical pregnancy in women with MS is si-
milar to that in women without MS, albeit with a tendency towards
increased use of assisted delivery/Caesarean section and possibly lower
neonatal birth weights (Hellwig, 2014; Oreja-Guevara et al., 2014).
Caesarean sections are not mandatory for women with relapsing re-
mitting MS, and any anesthetic choice or delivery method is acceptable
(Pasto et al., 2012). Epidural and spinal anesthesia are acceptable for
obstetric pain management in MS patients (Conradi et al., 2013;
Ragnedda et al., 2015), as their use has no impact on future disability or
disease activity; no correlation has been made between epidural an-
algesia use and postpartum relapses or disability progression (Lu et al.,
2013a; Pasto et al., 2012). Having MS does not create a high-risk
pregnancy, and duration of birth hospitalization is not extended
(Lu et al., 2013b). However, supportive care and counseling from MS
HCPs should be provided throughout all stages of pregnancy (Baird and
Dalton, 2013).
5. Postpartum
5.1. Disease activity
As mentioned previously, the first 3 months postpartum are a high-
risk period for increased clinical and magnetic resonance imaging
(MRI) disease activity, after which activity declines to pre-pregnancy
levels (Alroughani et al., 2018). In women at relatively high risk of
postpartum relapse (very active disease pre-pregnancy, poor prognostic
profile, relapse during pregnancy, and/or no prior DMT use), rapid re-
initiation of a DMT after delivery may be advisable (Coyle, 2016). Use
of corticosteroids can be considered for symptomatic treatment during
acute postpartum exacerbations of MS (Alroughani et al., 2016); how-
ever, while methylprednisolone transfer to breastmilk is minimal,
breastfeeding should be delayed between 2 and 4 h after treatment to
minimize infant exposure (Boz et al., 2017).
5.2. Breastfeeding
While the benefits of breastfeeding on infant health are well known,
its potential benefit of reducing disease activity in patients with MS is
inconclusive (Langer-Gould and Hellwig, 2013; Vukusic and
Confavreux, 2013). Mothers without relapses during pregnancy, or with
no active disease as indicated by MRI 2–4 months after delivery, may
choose to breastfeed for the WHO-recommended 6 months (Alroughani
et al., 2016; Hellwig et al., 2015). While some studies have found that
exclusive breastfeeding for at least 2 months after delivery can decrease
postpartum relapse risk (Hellwig et al., 2015), other researchers found
that breastfeeding had no influence on postpartum relapses (Jesus-
Ribeiro et al., 2017). Evidence also suggests that exclusive breast-
feeding by mothers with MS may offer the infant protection from MS
later in life (Conradi et al., 2013; Coyle, 2016; Ragnedda et al., 2015).
The decision to restart DMTs after delivery or breastfeeding is an
important issue for women living with MS. There is limited information
available on the safety of DMT use during lactation, as well as the ex-
tent of DMT transfer to breastmilk (Table 2) (Almas et al., 2016). IFNβ
and GA may be considered during lactation, as GA is considered safe,
with no known transfer to breastmilk, and negligible levels of IFNβ in
breastmilk have been detected (0.006% of the maternal dose) (Hale
et al., 2012; Teva Neuroscience, 2018). While the transfer of other
DMTs (e.g., fingolimod, cladribine, and DMF) to breastmilk has not
been confirmed, it is considered highly likely, and thus not re-
commended in breastfeeding mothers (Almas et al., 2016). With the
exception of natalizumab, which has been detected in breastmilk at
concentrations ranging from 2 to 412 ng/mL, it is unknown whether
other monoclonal antibodies (such as alemtuzumab and ocrelizumab)
are transferred into breastmilk (Almas et al., 2016; Biogen, 2018b;
Genentech Inc., 2018; Proschmann et al., 2018). Currently, women are
advised to discontinue monoclonal antibody use while breastfeeding.
6. Progressive forms of MS
There are limited data on the impact of progressive MS on obstetric
outcomes and vice versa. In a study of 973 women with clinically de-
finite MS, results suggested that pregnancy at a younger age and use of
oral contraceptives might adversely affect patients with progressive MS
(D'Hooghe et al., 2012). However, until further studies resolve this
question, pregnant women with progressive MS should be managed in a
similar manner to patients with relapsing MS (Coyle, 2016). In very
disabled patients, assisted vaginal delivery or Caesarean section may
need to be considered (Coyle, 2016).
Few studies have investigated the safety of DMTs in pregnant pa-
tients with progressive forms of MS. Ocrelizumab is indicated for use in
patients with primary progressive MS (Genentech Inc., 2018; Roche
Registration GmbH, 2018), although women of reproductive potential
are advised to continue to use contraception while receiving treatment,
and for 6–12 months after the last infusion (Genentech Inc., 2018;
Roche Registration GmbH, 2018).
7. Conclusions
While the care of women living with MS during pregnancy and the
peripartum period can be complex, this review attempts to summarize
the evidence and expert recommendations about specific issues in each
of these periods. Most patients with MS can safely become pregnant and
deliver healthy children, without adversely affecting their own health
or MS disease course (Coyle, 2016). As the prevalence of MS continues
to increase among women of reproductive potential, neurologists will
play a growing role in managing these MS patients during all stages of
family planning and pregnancy. Neurologists, primary care physicians,
and OB/GYNs will continue to help these patients make informed de-
cisions and choices related to pregnancy (Rasmussen et al., 2018).
Physician and patient education will be critical to increase comfort
level with pregnancy planning and improve safety and outcomes in this
group of patients.
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